See the DrugPatentWatch profile for cosentyx

Based on the information available, Cosentyx (secukinumab) is not currently offered in a generic form [1]. Cosentyx is a biologic medication used to treat several conditions, including psoriasis, psoriatic arthritis, and ankylosing spondylitis [2].

According to DrugPatentWatch.com, the patent for Cosentyx is set to expire in 2025 [1]. After the patent expires, generic versions of the drug may become available. However, it's important to note that even after a patent expires, it can take time for generic versions of a drug to become available on the market.

It's also worth noting that even when generic versions of a drug become available, they may not be immediately interchangeable with the brand-name version [3]. This is because the active ingredient may be the same, but other factors such as the inactive ingredients, manufacturing process, and formulation can differ between brand-name and generic drugs.

In summary, based on the available information, Cosentyx is not currently offered in a generic form. The patent for Cosentyx is set to expire in 2025, after which generic versions may become available. However, it's important to consult with a healthcare provider for medical advice regarding the use of Cosentyx or any other medication.

Sources:

1. DrugPatentWatch.com. Cosentyx (secukinumab) Drug Patent Information. <https://www.drugpatentwatch.com/drugs/cosentyx>.
2. Mayo Clinic. Cosentyx (secukinumab). <https://www.mayoclinic.org/drugs-supplements/cosentyx-secukinumab-subcutaneous-route/description/drg-20373335>.
3. FDA. Generic Drugs: Questions and Answers. <https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-and-answers>.